Atugen Gives Update on Cancer Drugs; Firm Aims To Be First in Clinic as Phase I Is Set for 1H 2007
November 02, 2006
Atugen Gives Update on Cancer Drugs; Firm Aims To Be First in Clinic as Phase I Is Set for 1H 2007
Atugen expects to begin phase I testing of its pancreatic cancer drug candidate in the first half of next year, while a phase I trial in lung cancer will start during the second half of the year.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Regulus Selects HCV Drug Candidate, Will Develop without Partner GSK
May 16, 2013 / Gene Silencing News - Scripps, Novartis Team Uncovers New Details of Guide RNA, Argonaute2 Interaction
May 16, 2013 / Gene Silencing News - Gradalis Releases New Clinical Data on Cancer Vaccine
May 16, 2013 / Gene Silencing News - Former Traversa Exec Forms New Company to Develop Oligo-modification Tech
May 16, 2013 / Gene Silencing News - Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News